Hepatitis A seroprevalence in adolescents and young adults in Mexico: A 2012 National Health and Nutrition Survey analysis.

Hugo López-Gatell, Lourdes García-García, Gabriela Echániz-Avilés, Pablo Cruz-Hervert, María Olamendi-Portugal, Deyanira Castañeda-Desales, Miguel Ángel Sanchez-Alemán, Martín Romero-Martínez, Rodrigo DeAntonio, Maria Yolanda Cervantes-Apolinar, Ricardo Cortes-Alcalá, Celia Alpuche-Aranda

Journal: Vaccine 2019;36(52):8094-8099

PMID: 30337174

Abstract

To describe hepatitis A virus (HAV) seroprevalence and associated factors in adolescents (10-19 years) and young adults (20-25 years) in different Mexican regions, using 2012 National Health and Nutrition Survey data. A random selection of 1581 serum samples was analyzed. Weighted HAV seroprevalence with 95% confidence intervals (95%CI) and its association with sociodemographic factors were estimated. Mean weighted HAV seroprevalence was 69.3% (95%CI: 64.8-73.4) overall, with 58.8% (95%CI: 53.4-64.1) in adolescents and 83.0% (95%CI: 75.3-88.7) in young adults. By age of 10, 46.7% (95%CI: 33.9-60.0) were seropositive and by age of 15, 52.8% (95%CI: 36.5-68.5), corresponding to intermediate endemicity nationally. Factors associated with HAV seropositivity (adjusted odds ratio, aOR) included: lower socioeconomic status (SES) (aOR = 4.09 for low and aOR = 2.31 for medium versus high SES), older age (aOR = 0.29 for adolescents versus young adults), living in the South (aOR = 2.12 versus Central Mexico) or in rural areas (aOR = 2.25 versus urban areas). Regional differences and increased seroprevalence of HAV in marginalized populations present an important public health issue, as a relatively large proportion of young adults are susceptible to infection. The burden of symptomatic disease must be addressed further to support specific programs of continued sanitation and education improvement, and the possibility of vaccination in more susceptible regions.

Copyright © 2018 GlaxoSmithKline Biologicals SA. Published by Elsevier Ltd.. All rights reserved.

Address: Centro de Investigación Sobre Enfermedades Infecciosas, Instituto Nacional de Salud Pública, Av. Universidad # 655, Col. Sta. María Ahuacatitlán, C.P. 62100 Cuernavaca, Morelos, Mexico.; Centro de Investigación sobre Evaluación y Encuestas, Instituto Nacional de Salud Pública, Av. Universidad # 655, Col. Sta. María Ahuacatitlán, C.P. 62100 Cuernavaca, Morelos, Mexico.; GSK, Urbanización Industrial Juan Díaz Entre Calles A y B, Apartado Postal 6-1697, Panama City, Panama; Cevaxin - Centro de Vacunación Internacional, Pan-American Hwy, Panama City, Panama.; GSK, Urbanización Industrial Juan Díaz Entre Calles A y B, Apartado Postal 6-1697, Panama City, Panama; GSK, Calz México-Xochimilco 4900, Col. San Lorenzo Huipulco, Mexico City 14370, Mexico.; GSK, Calz México-Xochimilco 4900, Col. San Lorenzo Huipulco, Mexico City 14370, Mexico.; Centro de Investigación Sobre Enfermedades Infecciosas, Instituto Nacional de Salud Pública, Av. Universidad # 655, Col. Sta. María Ahuacatitlán, C.P. 62100 Cuernavaca, Morelos, Mexico. Electronic address: [email protected].

Link outs

Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.